Ultime notizie per XIAO-I (NASDAQ:AIXI) Azioni

XIAO-I

XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.

XIAO-I Corporation - American Depositary Shares

XIAO-I Corp

AIXIN LIFE INTL INC by AiXin Life International, Inc.

AiXin Life International Inc

Aixia Group AB

Needham analyst Chris Pierce maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Buy and lowers the price target from $45 to $39.

News

Price Target

Analyst Ratings

CARG

Needham Maintains Buy on CarGurus, Lowers Price Target to $39

Earnings

Earnings Beats

Earnings Misses

ANIK

Anika Therapeutics Q1 Adj. EPS $(0.06) Beats $(0.14) Estimate, Sales $26.20M Miss $28.07M Estimate

Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) reported quarterly earnings of $0.72 per share which missed the analyst consensus estimate of $0.96 by 25 percent. This is a 5.88 percent increase over earnings of $0.68 per share from the same period last year.

Enbridge Q1 Adj. EPS $0.72 Misses $0.96 Estimate

Telsey Advisory Group analyst Dana Telsey maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and maintains $70 price target.

BIRK

Telsey Advisory Group Maintains Outperform on Birkenstock Holding, Maintains $70 Price Target

Guidance

ANIP

ANI Pharmaceuticals Raises FY2025 Adj EPS Guidance from $6.12-$6.49 to $6.27-$6.62 vs $6.34 Est; Raises FY2025 Sales Guidance from $756.00M-$776.00M to $768.00M-$793.00M vs $769.64M Est

Hedge-fund chief Spencer Hakimian says a U.S.–China tariff resolution could arrive soon, arguing that markets and the White House are signaling an about-face on tariffs.
What Happened: "I think there's an imminent de-escalation with China coming," he <a href="https://x.com/spencerhakimian/status/1920563405674721294?s=46&amp;t=RZNzAoNSau5h8D-rx-gkjQ">wrote</a> on X, outlining four red-flag clues.
<h4 class="wp-block-heading">Inventory clock Is Ticking</h4>
Hakimian warns the United States is "just weeks away from a full collapse of our economy without Chinese inventory." Trans-Pacific sailings that once took 17 days now average five to seven weeks, leaving retailers little slack if shipments stay frozen, reveals an Investor&#8217;s <a href="https://www.investors.com/news/trump-tariffs-trade-war-us-ports-empty/">report</a>.
<h4 class="wp-block-heading">Trump's Tariff Talk Whipsaws</h4>
On Wednesday, President Donald Trump <a href="https://www.benzinga.com/25/05/45273459/no-trump-shuts-down-tariff-rollback-buzz-ahead-of-china-talks">vowed</a> he "would not budge" on Beijing duties. Twenty-four hours later, aides floated cutting the headline 145% levy by more than half, speaking to Reuters, a move insiders say could emerge from <a href="https://www.benzinga.com/25/05/45242461/donald-trumps-trade-war-sparks-first-major-us-china-talks-scott-bessent-jamieson-greer-to-meet-chinese-delegation-in-geneva">talks in Switzerland</a> this weekend.
See also: <a href="https://www.benzinga.com/25/05/45312897/did-trump-backed-world-liberty-financial-bought-35-million-in-eth-heres-what-on-chain-data-says">Trump-Backed World Liberty Likely Scooped Up $3.5 Million In Ethereum — Here&#8217;s What On-Chain Data Shows</a>
<h4 class="wp-block-heading">Déjà vu In The Stock Market</h4>
Hakimian notes that Trump's X post <a href="https://www.benzinga.com/25/05/45294428/wall-street-rallies-after-us-seals-first-trade-deal-you-better-go-out-and-buy-stock-trump-says">urging investors</a> to "buy stocks today" echoes a similar call hours before the April 9, 90-day tariff pause that sent the S&amp;P 500 to record highs.
Risk-on Tape Backs Him Up
According to Reuters, Bitcoin&nbsp;(USD/ BTC) is up 15% in a month, oil has climbed 9%, and gold prices have slumped as haven trades unwind. Treasury yields, meanwhile, are spiking. "Really seems like the major market participants … know what is coming," Hakimian wrote.
Why It Matters: While White House advisors are certain that Trump&#8217;s &#8216;liberation day&#8217; tariffs have only <a href="https://www.benzinga.com/government/regulations/25/05/45284320/peter-schiff-rejects-larry-kudlows-claim-that-china-is-falling-apart-without-us-says-we-have-actually-been-their-worst-customer">signaled positives</a> for the market, economists like&nbsp;Peter Schiff&nbsp;believe that tariffs are chasing foreign capital out of U.S. assets and could spark a deeper <a href="https://www.benzinga.com/news/global/25/04/44781938/trump-tariffs-have-put-america-last-for-investors-peter-schiff-warns-of-a-financial-crisis-worse-than-2008">financial crisis</a>.
Meanwhile, economist Mohamed A. El-Erian has highlighted potential "<a href="https://www.benzinga.com/government/regulations/25/05/45311562/mohamed-el-erian-flags-adverse-implications-for-domestic-industries-as-chinas-exports-rise-8-despite-21-drop-in-us-shipments">adverse implications</a>" for domestic industries following a surprisingly strong surge in China's exports for April. Reports suggest that the escalating trade war with China is also triggering a <a href="https://www.benzinga.com/markets/25/05/45185792/young-americans-express-discontent-over-trumps-china-tariffs">negative response</a> among young voters, who were instrumental in Trump's election success.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/25/05/45312871/china-says-we-have-no-fear-ahead-of-crucial-us-trade-talks-in-switzerland-as-trump-signals-potential-tariff-reductions">China Says &#8216;We Have No Fear&#8217; Ahead Of Crucial US Trade Talks In Switzerland As Trump Signals Potential Tariff Reductions</a>

Government

Regulations

China De-escalation 'Imminent' Thinks Hedge Fund Manager Spencer Hakimian, Reveals Four Reasons Why

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) with a Buy and lowers the price target from $5 to $2.

ALXO

HC Wainwright & Co. Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $2

Gary Black says Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will capitalize on the growing EV adoption among drivers, as well as increasing demand for self-driving vehicles.
What Happened: Quoting a post on social media platform X, which asked Black's views on Elon Musk's EV giant's current trajectory, he shared his thoughts on Thursday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">TSLA's more affordable car strategy seems deja vu 2023-2024 &#8211; price cuts funded by cost cuts with no volume growth. We believe the Austin ride hailing test has asymmetrical risk/return. Long term we like the <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> story and hence own the name at a market weight. As EV adoption… <a href="https://t.co/8CB5ESnBeT">https://t.co/8CB5ESnBeT</a>
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1920504347001012556?ref_src=twsrc%5Etfw">May 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"TSLA's more affordable car strategy seems deja vu 2023-2024 &#8211; price cuts funded by cost cuts with no volume growth," he said as Tesla is <a href="https://www.benzinga.com/markets/equities/25/04/44755221/tesla-unveils-new-cybertruck-long-range-trim-with-a-362-mile-range-and-reduced-features">offering cheaper variants</a> of its models in the U.S. He added that the Austin robotaxi launch in June held an "asymmetrical risk/return."
However, the investor also shared that he was optimistic about the company's future. "Long term we like the $TSLA story." He said before adding, "As EV adoption and demand for autonomy increases, $TSLA remains the best positioned to capitalize on these two megatrends,"
Why It Matters: Tesla has been teasing the arrival of its Robotaxi in June, with CEO Musk confirming that there would at least be <a href="https://www.benzinga.com/news/earnings/25/04/44943387/elon-musk-shares-fsd-update-at-tesla-earnings-call-10-to-20-model-ys-will-offer-paid-robotaxi-rides-in-june">10-20 Model Y robotaxis</a> in Austin on launch day.
Tesla has also rolled out its robotaxi in <a href="https://www.benzinga.com/tech/25/04/44972108/tesla-quietly-launched-robotaxi-service-for-employees-before-june-debut-now-reports-1500-completed-trips">limited runs restricted to employees </a>in cities like Austin and San Francisco, where it has clocked more than 15,000 miles and 1,500 trips.
Elsewhere, the company has touted its self-driving capabilities with <a href="https://www.benzinga.com/tech/25/05/45213809/teslas-elon-musk-says-manually-driven-cars-will-be-unusual-in-the-future-shares-updates-on-spacex-neuralink">Musk expressing optimism</a> in the brand's FSD (Full Self-Driving) tech and went as far as to say that manually driven cars will become obsolete in the future.
However, Musk's robotaxi ambitions are <a href="https://www.benzinga.com/25/05/45278182/elon-musks-cybercab-ambitions-face-latest-snag-teslas-robotaxi-trademark-filing-refused-by-authorities">grappling with hurdles</a> as the USPTO or U.S. Patent and Trademark Office refused to grant the company trademarks for the terms "Robotaxi" as well as "Cybercab."
Price Action: TSLA gained 1.12% in Pre-market trading, with a current value of $288.02, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45311264/tesla-rival-lucid-offers-over-20000-discount-on-air-sedan-amid-auto-tariff-impact">Tesla Rival Lucid Offers Over $20,000 Discount On Air Sedan Amid Auto Tariff Impact</a></li>
</ul>
Photo Courtesy: Trygve Finkelsen on Shutterstock.com

Tech

TSLA

Tesla Bull Gary Black Reaffirms Elon Musk's Company 'Best Positioned To Capitalize' On EVs And Autonomous Driving, But There's A Catch

IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug
IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others
KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA
IND-enabling studies are ongoing with Phase 1 testing expected to begin in early 2026
Company to hold video webcast today at 10:00 a.m. ET as part of the release of first quarter 2025 results
WATERTOWN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=p-K33wV1eO-MwvAh5_u153KOBagQ8HOyJdopyhiiDIdI4r05PdJDHtEFY-hNOQKmSEs4IyGYrGrIft59WQKCVgfdSm7IS2UFICTBtaj3t84=">Kymera Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today unveiled a new wholly-owned program within its industry-leading oral immunology pipeline. KT-579, a highly potent, selective, first-in-class development candidate, targets IRF5, an essential signaling node in genetically and clinically validated immune pathways driving inflammation in many diseases with no or suboptimal oral options.&nbsp;The new program serves as a valuable addition to the Company's current portfolio, positioned to target multiple common immuno-inflammatory diseases with the potential to expand access to oral systemic advanced therapies for broader patient populations. Kymera will share preclinical data and outline upcoming milestones for KT-579 during a video webcast this morning.

KYMR

Kymera Therapeutics Expands Immunology Pipeline With KT-579, First-In-Class Oral IRF5 Degrader

Telsey Advisory Group analyst Dana Telsey maintains Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) with a Outperform and lowers the price target from $30 to $22.

WRBY

Telsey Advisory Group Maintains Outperform on Warby Parker, Lowers Price Target to $22

RPID

Rapid Micro Biosystems Reaffirms FY2025 Revenue Guidance Of $32M vs $32.55M Est.

Onex (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ONEXF#OTC">ONEXF</a>) reported quarterly earnings of $2.05 per share. This is a 521.21 percent increase over earnings of $0.33 per share from the same period last year. The company reported $201.00 million in sales this quarter. This is a 113.83 percent increase over sales of $94.00 million the same period last year.

ONEXF

Onex Q1 Adj. EPS $2.05 Up From $0.33 YoY, Sales $201.00M Up From $94.00M YoY

Telsey Advisory Group analyst Cristina Fernandez maintains Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Market Perform and maintains $10 price target.

ARHS

Telsey Advisory Group Maintains Market Perform on Arhaus, Maintains $10 Price Target

Second Quarter Outlook
<ul>
<li>Adjusted EBITDA of $75 million to $95 million</li>
<li>Compared to the first quarter:
<ul>
<li>Price and mix are expected to improve by $5 million to $10 million due to favorable mix in Latin America and North America</li>
<li>Volume is projected to remain stable in the range of $(5) million to $5 million</li>
<li>Operations and other costs are expected to improve by $10 million to $15 million primarily due to improving manufacturing operations and seasonally lower operating costs in Europe and North America</li>
<li>Input and transportation costs are projected to improve by $5 million to $10 million due to energy</li>
<li>Total planned maintenance outage expenses are expected to increase by $36 million</li>
</ul>
</li>
<li>We expect quarterly earnings to significantly improve in the second half of the year as we benefit from lower planned maintenance outage expenses, improved commercial results and better operations.</li>
</ul>

General

SLVM

Sylvamo Expects Q2 FY2025 Adjusted EBITDA Of $75M-$95M

CSTL

Castle Biosciences Unveils Real-World Data Supporting PRAME Integration to Enhance Uveal Melanoma Risk Prediction

Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.27) by 3.7 percent. This is a 16.13 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $7.21 million which beat the analyst consensus estimate of $6.60 million by 9.17 percent. This is a 28.41 percent increase over sales of $5.61 million the same period last year.

Rapid Micro Biosystems Q1 EPS $(0.26) Beats $(0.27) Estimate, Sales $7.21M Beat $6.60M Estimate

Needham analyst Laura Martin reiterates Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and maintains $84 price target.

Reiteration

Needham Reiterates Buy on Trade Desk, Maintains $84 Price Target

BKV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.15 by 173.33 percent. The company reported quarterly sales of $78.82 million which missed the analyst consensus estimate of $211.97 million by 62.82 percent. This is a 48.12 percent decrease over sales of $151.91 million the same period last year.

BKV Q1 Adj. EPS $0.41 Beats $0.15 Estimate, Sales $78.82M Miss $211.97M Estimate

BTDR

Bitdeer's April Bitcoin Production Jumps 45.6% To 166 BTC on SEALMINER Deployment

Telsey Advisory Group analyst Dana Telsey maintains Clear Secure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) with a Outperform and maintains $32 price target.

Comments

XIAO-I

Notizie

Ultime notizie per XIAO-I (NASDAQ:AIXI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO